<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542268</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-PTX</org_study_id>
    <nct_id>NCT01542268</nct_id>
  </id_info>
  <brief_title>Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)</brief_title>
  <acronym>IBS-PTX</acronym>
  <official_title>Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the therapeutics effectiveness of oral
      pentoxifylline treatment in patients with IBS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disruption of the intestinal epithelial barrier is part of the pathophysiology of IBS
      favoring immune activation present in the mucosa of these patients and the development of
      symptoms in IBS. To evaluate the effect of treatment with pentoxifylline (PTX) in patients
      with IBS related to clinical response and modulation of the components of the epithelial
      barrier at the level of intestinal mucosa.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of abdominal pain</measure>
    <time_frame>3 months from the first day of treatment</time_frame>
    <description>Clinical endpoint:
Average daily severity of abdominal pain on a 0-10 scale [ Time Frame: Week 0 to week 12 ] [ Designated as safety issue: No ] Days with urgency [ Time Frame: Week 0 to week 12 ] [ Designated as safety issue: No ] Mean stool consistency using Bristol Stool Form Score [ Time Frame: Week 0 to week 12 ] [ Designated as safety issue: No ] Global satisfaction with control of IBS symptoms as assessed from the answer to the question &quot;Have you had satisfactory relief of your IBS symptoms this week? Yes / No. &quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucosal byopsies</measure>
    <time_frame>3 months from the first day of treatment</time_frame>
    <description>Effect of pentoxifylline treatment from mucosal byopsies on:
epithelial morphology;
mucosal immune cell subsets;
changes of gene expression of genes related to intestinal epithelial barrier component( tight junctions)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pentoxifylline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxifylline</intervention_name>
    <description>Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.</description>
    <arm_group_label>pentoxifylline</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxifylline placebo</intervention_name>
    <description>Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.</description>
    <arm_group_label>pentoxifylline placebo</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years old

          -  Most of the patient with IBS will be chose between the patients who go to Digestive
             System ambulatory external medical office from our Center.

          -  Be studied and with clinical monitoring al least 6 months before be included.

          -  Fulfill with Roma III Criteria for IBS (Gastroenterology 2006;130:1377-90) with
             moderate-severe seriousness according to Modification Francis Scale

        Exclusion Criteria:

          -  2 weeks before colon biopsia, any patient cann´t take salicylates, NSAID,
             antibiotics,anticholinergics,opiates or any other medication / product for asintomatic
             treatment of diarrea.

          -  3 months before colon biopsia, any patient cann´t take medicaments as corticoides,
             antihistamines or immunosuppressive

          -  6 months before colon biopsia, any patient cann´t recive radiotherapy or chemotherapy.

          -  Pentoxifilina Alergic Reactions

          -  Pregnants

          -  Grave kidney failure

          -  Grave Hepatic failure

          -  Menthal or legal disability to sign the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURA RAMOS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO UNIVERSITARIO DE CANARIAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAURA RAMOS, MD</last_name>
    <phone>+34 922675557</phone>
    <email>laura7ramos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ANA ALDEA, MD</last_name>
    <phone>+34922678115</phone>
    <email>a.aldea@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>S/c Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LAURA RAMOS, MD</last_name>
      <phone>+34 922675557</phone>
      <email>laura7ramos@gmial.com</email>
    </contact>
    <contact_backup>
      <last_name>ANA ALDEA, MD</last_name>
      <phone>+34922678115</phone>
      <email>a.aldea@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>LAURA RAMOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pentoxifylline</keyword>
  <keyword>tight junction signalling</keyword>
  <keyword>intestinal epithelial barrier</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

